Ultime notizie per SRAX (OTC:SRAX) Azioni

SRAX

SRAX Inc is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track investor's behavior and trends and use those insights to engage current and potential investors across marketing channels.

Social Reality

SRAX Inc

<p>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Atomera will report an <strong>earnings per share</strong> (EPS) of $-0.14.</p>
<p>The market awaits Atomera's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 38.5% drop in the share price the following trading session.</p>
<p>Here's a look at Atomera's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.14</td>
<td>0</td>
<td>-0.15</td>
<td>-0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-38.0%</td>
<td>28.000000000000004%</td>
<td>13.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471783_0.png" alt="eps graph" /></p>
<h3>Market Performance of Atomera's Stock</h3>
<p>Shares of Atomera were trading at $5.02 as of May 02. Over the last 52-week period, shares are up 15.33%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ATOM/earnings"><strong>To track all earnings releases for Atomera visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ATOM

Atomera's Earnings Outlook

<p><strong>WideOpenWest</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOW#NYSE">WOW</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that WideOpenWest will report an <strong>earnings per share</strong> (EPS) of $-0.19. </p>
<p>Investors in WideOpenWest are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at WideOpenWest's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.13</td>
<td>-0.10</td>
<td>-0.15</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.13</td>
<td>-0.27</td>
<td>-0.13</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471769_0.png" alt="eps graph" /></p>
<h3>Market Performance of WideOpenWest's Stock</h3>
<p>Shares of WideOpenWest were trading at $4.49 as of May 02. Over the last 52-week period, shares are down 5.82%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WOW/earnings"><strong>To track all earnings releases for WideOpenWest visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at WideOpenWest's Future Earnings

<p><strong>Ranpak Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ranpak Hldgs will report an <strong>earnings per share</strong> (EPS) of $-0.04. </p>
<p>Ranpak Hldgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.06 in the last quarter, leading to a 5.92% drop in the share price on the following day.</p>
<p>Here's a look at Ranpak Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.04</td>
<td>-0.06</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.10</td>
<td>0.07</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>0.0%</td>
<td>-9.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471761_0.png" alt="eps graph" /></p>
<h3>Market Performance of Ranpak Hldgs's Stock</h3>
<p>Shares of Ranpak Hldgs were trading at $4.42 as of May 02. Over the last 52-week period, shares are down 38.5%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PACK/earnings"><strong>To track all earnings releases for Ranpak Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PACK

Ranpak Hldgs's Earnings: A Preview

WIIM

Sotera Health shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $14 to $17.

<p><strong>Myriad Genetics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Myriad Genetics will report an <strong>earnings per share</strong> (EPS) of $-0.06. </p>
<p>Investors in Myriad Genetics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 14.8% drop in the share price the next day.</p>
<p>Here's a look at Myriad Genetics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.02</td>
<td>-0.01</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.03</td>
<td>0.06</td>
<td>0.05</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-15.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>21.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471745_0.png" alt="eps graph" /></p>
<h3>Myriad Genetics Share Price Analysis</h3>
<p>Shares of Myriad Genetics were trading at $7.56 as of May 02. Over the last 52-week period, shares are down 61.02%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MYGN/earnings"><strong>To track all earnings releases for Myriad Genetics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MYGN

Myriad Genetics's Earnings: A Preview

<p>Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Harmony Biosciences to report an <strong>earnings per share</strong> (EPS) of $1.09.</p>
<p>The market awaits Harmony Biosciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.26, leading to a 9.47% drop in the share price the following trading session.</p>
<p>Here's a look at Harmony Biosciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.82</td>
<td>0.66</td>
<td>-0.06</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.08</td>
<td>1.03</td>
<td>1.05</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-19.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471737_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Harmony Biosciences were trading at $30.32 as of May 02. Over the last 52-week period, shares are down 3.16%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Harmony Biosciences</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Harmony Biosciences.</p>
<p>Harmony Biosciences has received a total of 12 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $54.5, the consensus suggests a potential 79.75% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Supernus Pharmaceuticals and ANI Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $36.0, suggesting a potential 18.73% upside.</li>
<li>Analysts currently favor an Buy trajectory for ANI Pharmaceuticals, with an average 1-year price target of $84.29, suggesting a potential 178.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Supernus Pharmaceuticals and ANI Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harmony Biosciences Hldgs</td>
<td>Buy</td>
<td>19.51%</td>
<td>$146.86M</td>
<td>7.88%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>5.99%</td>
<td>$148.06M</td>
<td>1.50%</td>
</tr>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Buy</td>
<td>44.75%</td>
<td>$110.29M</td>
<td>-2.64%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Harmony Biosciences ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>Delving into Harmony Biosciences's Background</h3>
<p>Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.</p>
<h3>Harmony Biosciences: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Harmony Biosciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.51%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Harmony Biosciences's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.58%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.88%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Harmony Biosciences's ROA excels beyond industry benchmarks, reaching <strong>5.13%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Harmony Biosciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.27</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/HRMY/earnings"><strong>To track all earnings releases for Harmony Biosciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HRMY

Harmony Biosciences's Earnings: A Preview

<p>Financial giants have made a conspicuous bearish move on Maplebear. Our analysis of options history for Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 12% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $199,200, and 3 were calls, valued at $272,000.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $50.0 for Maplebear over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Maplebear's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Maplebear's substantial trades, within a strike price spectrum from $45.0 to $50.0 over the preceding 30 days.</p>
<h3>Maplebear Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471736_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$45.00</td>
<td>$157.4K</td>
<td>543</td>
<td align="right">300</td>
</tr>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$45.00</td>
<td>$88.5K</td>
<td>543</td>
<td align="right">108</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.6</td>
<td>$7.4</td>
<td>$7.6</td>
<td>$50.00</td>
<td>$48.6K</td>
<td>1.3K</td>
<td align="right">277</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.8</td>
<td>$50.00</td>
<td>$43.6K</td>
<td>1.3K</td>
<td align="right">369</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.6</td>
<td>$50.00</td>
<td>$38.0K</td>
<td>1.3K</td>
<td align="right">179</td>
</tr>
</tbody>
</table>
</p>
<h3>About Maplebear</h3>
<p>Maplebear (Instacart) operates a leading grocery delivery platform in the United States and Canada. The company partners with various regional and national grocers, which offer their selection of food and other goods to customers through Instacart's ubiquitous platform. Once an item is ordered through Instacart's site, the item is picked and delivered to the customer's home by one of the platform's 600,000 shoppers, who are classified as independent contractors. Instacart earns fees based on average order value and leverages its platform's high usage to sell advertising, mainly to consumer-packaged goods companies. Instacart currently has around 8 million monthly active users (or orderers) on its platform.</p>
<p>Following our analysis of the options activities associated with Maplebear, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Maplebear Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,993,897, the price of CART is up by 4.31%, reaching $47.17.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 92 days from now.</li>
</ul>
<h3>Expert Opinions on Maplebear</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $54.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Maplebear, which currently sits at a price target of $54.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Maplebear, targeting a price of $44.<br />
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $55.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $56.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Maplebear, targeting a price of $61. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Maplebear options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

CART

Maplebear's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 54% leaning bullish and 45% bearish. Among these notable options, 8 are puts, totaling $1,584,258, and 3 are calls, amounting to $92,140.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $175.0 for Applied Mat, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $135.0 to $175.0, over the past month.</p>
<h3>Applied Mat Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471731_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.05</td>
<td>$150.00</td>
<td>$814.5K</td>
<td>2.1K</td>
<td>909</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.57</td>
<td>$155.00</td>
<td>$560.6K</td>
<td>499</td>
<td>1.1K</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.65</td>
<td>$5.5</td>
<td>$5.65</td>
<td>$155.00</td>
<td>$53.6K</td>
<td>499</td>
<td>14</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.35</td>
<td>$21.5</td>
<td>$22.13</td>
<td>$175.00</td>
<td>$44.2K</td>
<td>2.4K</td>
<td>20</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$13.3</td>
<td>$12.75</td>
<td>$13.3</td>
<td>$145.00</td>
<td>$37.2K</td>
<td>1.0K</td>
<td>30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Applied Mat</h3>
<p>Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.</p>
<p>After a thorough review of the options trading surrounding Applied Mat, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Applied Mat</h3>
<ul>
<li>With a volume of 2,302,788, the price of AMAT is up 0.73% at $156.24. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 10 days.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $178.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Applied Mat with a target price of $195.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Applied Mat, targeting a price of $170.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Applied Mat, maintaining a target price of $190.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Applied Mat, which currently sits at a price target of $160. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Applied Mat, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AMAT

Market Whales and Their Recent Bets on AMAT Options

<p>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Evotec to report an <strong>earnings per share</strong> (EPS) of $-0.24.</p>
<p>Evotec bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.11 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Evotec's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.100</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.065</td>
<td></td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>10.0%</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471727_0.png" alt="eps graph" /></p>
<h3>Tracking Evotec's Stock Performance</h3>
<p>Shares of Evotec were trading at $4.29 as of May 02. Over the last 52-week period, shares are down 17.9%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EVO/earnings"><strong>To track all earnings releases for Evotec visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: Evotec

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Strategy</strong>.</p>
<p>Looking at options history for Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) we detected 234 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 43% with bearish.</p>
<p>From the overall spotted trades, 66 are puts, for a total amount of $5,269,103 and 168, calls, for a total amount of $13,737,995.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $800.0 for Strategy during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Strategy's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Strategy's whale activity within a strike price range from $10.0 to $800.0 in the last 30 days. </p>
<h3>Strategy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471726_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$352.6</td>
<td>$351.9</td>
<td>$352.6</td>
<td>$710.00</td>
<td>$1.0M</td>
<td>42</td>
<td align="right">30</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$47.1</td>
<td>$46.6</td>
<td>$47.0</td>
<td>$500.00</td>
<td>$470.0K</td>
<td>3.8K</td>
<td align="right">113</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$166.75</td>
<td>$165.5</td>
<td>$166.75</td>
<td>$410.00</td>
<td>$333.5K</td>
<td>47</td>
<td align="right">20</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$379.2</td>
<td>$377.5</td>
<td>$378.4</td>
<td>$10.00</td>
<td>$264.8K</td>
<td>1.2K</td>
<td align="right">28</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$33.9</td>
<td>$33.7</td>
<td>$33.7</td>
<td>$380.00</td>
<td>$168.5K</td>
<td>871</td>
<td align="right">276</td>
</tr>
</tbody>
</table>
</p>
<h3>About Strategy</h3>
<p>Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.</p>
<p>Having examined the options trading patterns of Strategy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Strategy</h3>
<ul>
<li>With a trading volume of 9,875,095, the price of MSTR is down by -1.48%, reaching $388.55.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 87 days from now.</li>
</ul>
<h3>What The Experts Say On Strategy</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $510.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $480.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Strategy, targeting a price of $464.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Strategy, maintaining a target price of $521.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Strategy, which currently sits at a price target of $475.<br />
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Strategy with a target price of $614. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Strategy with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


MSTR

Strategy Unusual Options Activity

<p><strong>Hyster Yale</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Hyster Yale will report an <strong>earnings per share</strong> (EPS) of $0.49. </p>
<p>Hyster Yale bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 2.84% increase in the share price the next day.</p>
<p>Here's a look at Hyster Yale's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.39</td>
<td>1.97</td>
<td>2.11</td>
<td>2.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.47</td>
<td>0.97</td>
<td>3.58</td>
<td>2.93</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>5.0%</td>
<td>-16.0%</td>
<td>24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471719_0.png" alt="eps graph" /></p>
<h3>Performance of Hyster Yale Shares</h3>
<p>Shares of Hyster Yale were trading at $40.33 as of May 02. Over the last 52-week period, shares are down 32.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HY/earnings"><strong>To track all earnings releases for Hyster Yale visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Hyster Yale's Earnings Potential

<p>Across the recent three months, 10 analysts have shared their insights on CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.8, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 0.83% decrease, the current average has fallen from the previous average price target of $10.89. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471692_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive CryoPort. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CryoPort compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of CryoPort's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CryoPort's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CryoPort analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About CryoPort</h2>
<p>CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.</p>
<h3>Understanding the Numbers: CryoPort's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> CryoPort's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>3.97%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-34.73%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-5.49%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.94%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> CryoPort's debt-to-equity ratio is below the industry average at <strong>0.68</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CYRX

Forecasting The Future: 10 Analyst Projections For CryoPort

<p>Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Lineage and provided 12-month price targets. The average target is $64.92, accompanied by a high estimate of $75.00 and a low estimate of $49.00. Highlighting a 13.32% decrease, the current average has fallen from the previous average price target of $74.90. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471673_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Lineage among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$59.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Thillman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$56.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$59.00</td>
<td>-</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Craig Mailman</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$74.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Nicholas Thillman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lineage. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lineage compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Lineage's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Lineage's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LINE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lineage analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lineage</h2>
<p>Lineage Inc is a temperature-controlled warehouse real estate investment trust. It operates an interconnected global temperature-controlled warehouse network, comprising approximately millions of square feet across several warehouses predominantly located in densely populated critical-distribution markets across North America, Asia-Pacific, and Europe. The company's reportable segments are Global Warehousing, which utilizes the company's industrial real estate properties to provide temperature-controlled warehousing services to its customers, and Global Integrated Solutions, which complements Global Warehousing with specialized cold-chain services. Maximum revenue is generated from the Global Warehousing segment. Geographically, the company derives its key revenue from the United States.</p>
<h3>Unraveling the Financial Story of Lineage</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Lineage's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-2.71%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Lineage's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lineage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Lineage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.01%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Lineage's debt-to-equity ratio is below the industry average. With a ratio of <b>0.83</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LINE

What 12 Analyst Ratings Have To Say About Lineage

<p>Throughout the last three months, 5 analysts have evaluated OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $239.0, a high estimate of $260.00, and a low estimate of $210.00. This current average reflects an increase of 7.42% from the previous average price target of $222.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471658_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of OSI Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Glynn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jeff Martin</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Josh Nichols</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Seth Seifman</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$225.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OSI Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OSI Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for OSI Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OSI Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OSIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on OSI Systems analyst ratings.</strong></a></p>
<h2>All You Need to Know About OSI Systems</h2>
<p>OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. Majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East, and Africa, and the Asia Pacific regions.</p>
<h3>Breaking Down OSI Systems's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> OSI Systems's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>5.84%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.26%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> OSI Systems's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.82%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> OSI Systems's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.95%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> OSI Systems's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.72</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OSIS

Beyond The Numbers: 5 Analysts Discuss OSI Systems Stock

<p>FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.47, along with a high estimate of $6.40 and a low estimate of $3.00. This current average represents a 1.54% decrease from the previous average price target of $4.54. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471648_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of FuboTV by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$6.40</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.35</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$6.40</td>
<td>$6.40</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FuboTV. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FuboTV compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of FuboTV's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FUBO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on FuboTV analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind FuboTV</h2>
<p>FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.</p>
<h3>FuboTV's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> FuboTV's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>8.07%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> FuboTV's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-8.7%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> FuboTV's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.85%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> FuboTV's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-3.54%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.93</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FUBO

Beyond The Numbers: 4 Analysts Discuss FuboTV Stock

<p>Analysts' ratings for JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $42.92, a high estimate of $48.00, and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 8.44% increase from the previous average price target of $39.58.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471636_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of JFrog's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mark Cash</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to JFrog. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of JFrog compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of JFrog's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FROG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on JFrog analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind JFrog</h2>
<p>JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.</p>
<h3>JFrog's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> JFrog displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.35%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> JFrog's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-19.98%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> JFrog's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-3.03%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> JFrog's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.1%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> JFrog's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FROG

What 13 Analyst Ratings Have To Say About JFrog

<p><strong>DraftKings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NYSE">DKNG</a>) short percent of float has fallen 8.29% since its last report. The company recently reported that it has <strong>24.31 million shares sold short</strong>, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.8 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>DraftKings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471631_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DraftKings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing DraftKings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, DraftKings's peer group average for short interest as a percentage of float is 5.73%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

DKNG

Peering Into DraftKings's Recent Short Interest

<p><strong>FedEx's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) short percent of float has fallen 3.37% since its last report. The company recently reported that it has <strong>3.78 million shares sold short</strong>, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.51 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>FedEx Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471625_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for FedEx has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing FedEx's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, FedEx's peer group average for short interest as a percentage of float is 3.72%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into FedEx's Recent Short Interest

<p>Ratings for Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $92.3, a high estimate of $111.00, and a low estimate of $77.00. This current average represents a 7.14% decrease from the previous average price target of $99.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746471624_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Ingersoll Rand among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$77.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$91.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$94.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ingersoll Rand. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ingersoll Rand compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ingersoll Rand's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ingersoll Rand's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ingersoll Rand analyst ratings.</strong></a></p>
<h2>All You Need to Know About Ingersoll Rand</h2>
<p>Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.</p>
<h3>A Deep Dive into Ingersoll Rand's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Challenges:</strong> Ingersoll Rand's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-9.58%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Ingersoll Rand's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>10.86%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ingersoll Rand's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.81%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ingersoll Rand's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.03%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ingersoll Rand's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.46</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Ingersoll Rand Through The Eyes Of 10 Analysts

<p>In the current market session, <strong>YETI Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>)</strong> share price is at $28.66, after a <strong>0.62%</strong> drop. Over the past month, the stock went up by <strong>6.26%</strong>, but over the past year, it actually decreased by <strong>18.90%</strong>. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746471621_0.png" alt="Past Year Chart" /></p>

<h3>How Does YETI Holdings P/E Compare to Other Companies?</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>YETI Holdings has a lower P/E than the aggregate P/E of <strong>20.5</strong> of the Leisure Products industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746471621_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Comments

SRAX

Notizie

Ultime notizie per SRAX (OTC:SRAX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO